Inclusion Criteria:

- HCC diagnosed by positive biopsy or non-invasive criteria,

- not suitable for surgical resection or transplantation,

- have at least one, but less than or equal to 3 tumors,

- of the tumour(s) identified, each tumor must be ≤ 3 cm in diameter,

- Child-Pugh class A,

- Eastern Cooperative Oncology Group (ECOG) score of 0,

- American Society of Anaesthesiologists (ASA) score ≤ 3,

- a prothrombin time ratio > 50%,

- platelet count > 50x109/L,

- ability of patient to stop anticoagulant and anti-platelet therapy for seven days
prior to and seven days post NanoKnife procedure,

- are able to comprehend and willing to sign the written informed consent form (ICF),

- have a life expectancy of at least 3 months.

Exclusion Criteria:

- eligible for surgical treatment or transplantation for HCC,

- presence of vascular invasion or extrahepatic metastases,

- received previous treatment for HCC,

- HCC developed on an already transplanted liver,

- cardiac insufficiency, ongoing coronary artery disease or arrhythmia,

- any active implanted device (eg Pacemaker),

- women who are pregnant or women of child-bearing potential who are not using an
acceptable method of contraception,

- have received treatment with an investigational agent/ procedure within 30 days prior
to treatment with the NanoKnife™ LEDC System,

- are in the opinion of the Investigator unable to comply with the visit schedule and
protocol evaluations.